

# **Olympus Corporation and Consolidated Subsidiaries**

## **INTERIM FINANCIAL RESULTS** For the Half Year Ended September 30, 2003

### **Table of Contents**

Income Statement	1
Sales by Product	2
Sales by Region	3
Operating Income by Segment (Product)	4
Operating Income by Segment (Region)	5
Income Statement (Forecast)	6
Sales by Product (Forecast)	7
Operating Income by Segment (Forecast)	8
Balance Sheet	9

#### **Cautionary Statements with respect to Forward-Looking Statements**

This report contains forward-looking statements that reflect management's current views, plans and expectations. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause Olympus's actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements.

# INCOME STATEMENT

(Millions of Yen)					
For the Half Year ended:	30-Sep 2002		<b>30-Sep 2003</b>		Growth (%)
Net Sales	259,873	100.0%	<b>299,664</b>	100.0%	15.3%
<u>Cost of Sales</u>	<u>135,107</u>	52.0%	<b><u>152,311</u></b>	50.8%	
Gross Profit	124,766	48.0%	<b>147,353</b>	49.2%	18.1%
<u>S.G.A. Expenses</u>	<u>96,285</u>	37.1%	<b><u>113,879</u></b>	38.0%	
Operating Income	28,481	11.0%	<b>33,474</b>	11.2%	17.5%
Other Income	2,640		<b>2,870</b>		
<u>Other Expenses</u>	<u>5,072</u>		<b><u>10,275</u></b>		
<u>Extraordinary Item</u>	<u>-3,730</u>		<b><u>-621</u></b>		
Income Before Taxes	22,319	8.6%	<b>25,448</b>	8.5%	14.0%
<u>Provision for Taxes</u>	<u>8,927</u>		<b><u>9,961</u></b>		
Net Income	13,392	5.2%	<b>15,487</b>	5.2%	15.6%
<hr/>					
Average Exchange Rate for Sales					
Yen / U.S.Dollar	123.14		<b>118.05</b>		-4.1%
Yen / Euro	116.94		<b>133.46</b>		14.1%
Favorable/Unfavorable Impact on Sales					
U.S.Dollar	718		<b>-4,136</b>		
Euro	4,790		<b>10,636</b>		
<u>Others</u>	<u>494</u>		<b><u>438</u></b>		
Total	6,002		<b>6,938</b>		
<hr/>					
R & D Expenditures	16,531	6.4%	<b>19,113</b>	6.4%	15.6%
Capital Investments	14,771		<b>18,784</b>		27.2%
Depreciation	8,430		<b>11,077</b>		31.4%

# SALES BY PRODUCT

(Millions of Yen)

For the Half Year ended:		30-Sep		30-Sep		Growth(%)		31-Mar		
		2002		2003				2003		
<b>Imaging</b>	<b>Cameras</b>	Domestic	2,422		<b>1,162</b>		-52.0%	4,879		
		Overseas	<u>25,644</u>		<u>15,199</u>		-40.7%	<u>49,083</u>		
		Total	28,066	10.8%	<b>16,361</b>	5.4%	-41.7%	53,962	9.6%	
	<b>Digital Cameras</b>	Domestic	17,481		<b>22,166</b>		26.8%	35,056		
		Overseas	<u>53,238</u>		<u>91,039</u>		71.0%	<u>139,787</u>		
		Total	70,719	27.2%	<b>113,205</b>	37.8%	60.1%	174,843	31.0%	
	<b>Voice Recorders</b>	Domestic	744		<b>1,088</b>		46.2%	1,519		
		Overseas	<u>5,014</u>		<u>5,779</u>		15.3%	<u>10,089</u>		
		Total	5,758	2.2%	<b>6,867</b>	2.3%	19.3%	11,608	2.1%	
	<b>Digital Storage</b>	Domestic	2,166		<b>1,416</b>		-34.6%	4,231		
		Overseas	<u>90</u>		<u>15</u>		-83.3%	<u>170</u>		
		Total	2,256	0.9%	<b>1,431</b>	0.5%	-36.6%	4,401	0.8%	
	<b>Total</b>	Domestic	22,813		<b>25,832</b>		13.2%	45,685		
		Overseas	<u>83,987</u>		<u>112,032</u>		33.4%	<u>199,129</u>		
		Total	106,800	41.1%	<b>137,864</b>	46.0%	29.1%	244,814	43.4%	
<b>Medical</b>	<b>Endoscopes</b>	Domestic	16,575		<b>19,758</b>		19.2%	36,265		
		Overseas	<u>45,345</u>		<u>46,753</u>		3.1%	<u>93,742</u>		
		Total	61,920	23.8%	<b>66,511</b>	22.2%	7.4%	130,007	23.0%	
	<b>MIP (*)</b>	Domestic	10,772		<b>10,623</b>		-1.4%	21,835		
		Overseas	<u>23,762</u>		<u>28,795</u>		21.2%	<u>49,670</u>		
		Total	34,534	13.3%	<b>39,418</b>	13.2%	14.1%	71,505	12.7%	
	<b>Total</b>	Domestic	27,347		<b>30,381</b>		11.1%	58,100		
		Overseas	<u>69,107</u>		<u>75,548</u>		9.3%	<u>143,412</u>		
		Total	96,454	37.1%	<b>105,929</b>	35.3%	9.8%	201,512	35.7%	
	<b>Life Science</b>	<b>Microscopes(Research)</b>	Domestic	5,305		<b>5,301</b>		-0.1%	11,747	
			Overseas	<u>9,880</u>		<u>10,883</u>		10.2%	<u>21,404</u>	
			Total	15,185	5.9%	<b>16,184</b>	5.4%	6.6%	33,151	5.9%
		<b>Blood Analyzers</b>	Domestic	3,795		<b>3,204</b>		-15.6%	7,314	
			Overseas	<u>11,921</u>		<u>13,909</u>		16.7%	<u>26,477</u>	
			Total	15,716	6.0%	<b>17,113</b>	5.7%	8.9%	33,791	6.0%
<b>Total</b>		Domestic	9,100		<b>8,505</b>		-6.5%	19,061		
		Overseas	<u>21,801</u>		<u>24,792</u>		13.7%	<u>47,881</u>		
		Total	30,901	11.9%	<b>33,297</b>	11.1%	7.8%	66,942	11.9%	
<b>Industrial</b>		<b>Microscopes(Industrial)</b>	Domestic	3,933		<b>3,601</b>		-8.4%	7,464	
			Overseas	<u>4,206</u>		<u>4,054</u>		-3.6%	<u>9,499</u>	
			Total	8,139	3.1%	<b>7,655</b>	2.7%	-5.9%	16,963	3.0%
		<b>Endoscopes(Industrial)</b>	Domestic	661		<b>692</b>		4.7%	1,370	
			Overseas	<u>3,750</u>		<u>3,892</u>		3.8%	<u>7,875</u>	
			Total	4,411	1.7%	<b>4,584</b>	1.5%	3.9%	9,245	1.6%
	<b>Printers</b>	Domestic	481		<b>1,151</b>		139.3%	971		
		Overseas	<u>2,186</u>		<u>1,192</u>		-45.5%	<u>3,851</u>		
		Total	2,667	1.0%	<b>2,343</b>	0.8%	-12.1%	4,822	0.9%	
	<b>Bar-Code Scanners</b>	Domestic	281		<b>209</b>		-25.6%	460		
		Overseas	<u>5,799</u>		<u>4,286</u>		-26.1%	<u>11,043</u>		
		Total	6,080	2.4%	<b>4,495</b>	1.5%	-26.1%	11,503	2.0%	
	<b>Others</b>	Domestic	696		<b>554</b>		-20.4%	1,403		
		Overseas	<u>286</u>		<u>96</u>		-66.4%	<u>527</u>		
		Total	982	0.4%	<b>650</b>	0.2%	-33.8%	1,930	0.3%	
<b>Total</b>	Domestic	6,052		<b>6,207</b>		2.6%	11,668			
	Overseas	<u>16,227</u>		<u>13,520</u>		-16.7%	<u>32,795</u>			
	Total	22,279	8.6%	<b>19,727</b>	6.6%	-11.5%	44,463	7.9%		
<b>Others</b>	Domestic	3,346		<b>2,667</b>		-20.3%	6,507			
	Overseas	<u>93</u>		<u>180</u>		93.5%	<u>105</u>			
	Total	3,439	1.3%	<b>2,847</b>	1.0%	-17.2%	6,612	1.2%		
<b>Total</b>	Domestic	68,658		<b>73,592</b>		7.2%	141,021			
	Overseas	<u>191,215</u>		<u>226,072</u>		18.2%	<u>423,322</u>			
	Total	259,873	100.00%	<b>299,664</b>	100.00%	15.31%	564,343	100.0%		

\* MIP: Endoscopes (Surgical), Endo-Therapy Accessories, Ultrasonic Endoscopes, Bronchoscopes

## SALES BY REGION

		(Millions of Yen)				
For the Half Year ended:		30-Sep 2002		30-Sep 2003		Growth (%)
<b>Imaging</b>	Japan	22,813	21.4%	<b>25,832</b>	18.7%	13.2%
	N. America	36,748	34.4%	<b>36,995</b>	26.8%	0.7%
	Europe	30,695	28.7%	<b>49,284</b>	35.8%	60.6%
	Asia	15,402	14.4%	<b>23,674</b>	17.2%	53.7%
	<u>Others</u>	1,142	1.1%	<b>2,079</b>	1.5%	82.0%
	<b>Total</b>	<u>106,800</u>		<u><b>137,864</b></u>		<u>29.1%</u>
<b>Medical</b>	Japan	27,347	28.4%	<b>30,381</b>	28.7%	11.1%
	N. America	35,630	36.9%	<b>37,299</b>	35.2%	4.7%
	Europe	26,432	27.4%	<b>31,038</b>	29.3%	17.4%
	Asia	5,296	5.5%	<b>4,971</b>	4.7%	-6.1%
	<u>Others</u>	1,749	1.8%	<b>2,240</b>	2.1%	28.1%
	<b>Total</b>	<u>96,454</u>		<u><b>105,929</b></u>		<u>9.8%</u>
<b>Life Science</b>	Japan	9,100	29.4%	<b>8,505</b>	25.6%	-6.5%
	N. America	9,311	30.1%	<b>9,448</b>	28.4%	1.5%
	Europe	8,490	27.5%	<b>11,487</b>	34.5%	35.3%
	Asia	3,406	11.0%	<b>3,369</b>	10.1%	-1.1%
	<u>Others</u>	594	2.0%	<b>488</b>	1.5%	-17.8%
	<b>Total</b>	<u>30,901</u>		<u><b>33,297</b></u>		<u>7.8%</u>
<b>Industrial</b>	Japan	6,052	27.2%	<b>6,207</b>	31.5%	2.6%
	N. America	9,903	44.5%	<b>6,382</b>	32.4%	-35.6%
	Europe	3,122	14.0%	<b>3,566</b>	18.1%	14.2%
	Asia	3,040	13.6%	<b>3,128</b>	15.9%	2.9%
	<u>Others</u>	162	0.7%	<b>444</b>	2.3%	174.1%
	<b>Total</b>	<u>22,279</u>		<u><b>19,727</b></u>		<u>-11.5%</u>
<b>Others</b>	Japan	3,346	97.3%	<b>2,667</b>	93.7%	-20.3%
	N. America	24	0.7%	-		-
	Europe	-		-		-
	Asia	69	2.0%	<b>180</b>	6.3%	160.9%
	<u>Others</u>	-		-		-
	<b>Total</b>	<u>3,439</u>		<u><b>2,847</b></u>		<u>-17.2%</u>
<b>Total</b>	Japan	68,658	26.4%	<b>73,592</b>	24.6%	7.2%
	N. America	91,616	35.3%	<b>90,124</b>	30.1%	-1.6%
	Europe	68,739	26.5%	<b>95,375</b>	31.8%	38.7%
	Asia	27,213	10.5%	<b>35,322</b>	11.8%	29.8%
	<u>Others</u>	3,647	1.3%	<b>5,251</b>	1.7%	44.0%
	<b>Total</b>	<u>259,873</u>		<u><b>299,664</b></u>		<u>15.3%</u>

## OPERATING INCOME BY SEGMENT (Product Group)

<b>By Product Group</b>	(Millions of Yen)						
for the Half Year ended;	<b>Sep 30</b>						
	<b>2003</b>						
	<b>Imaging</b>	<b>Medical</b>	<b>Life Science</b>	<b>Industrial</b>	<b>Others</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	137,877	105,935	33,311	19,736	2,848	(43)	299,664
<u>Operating Expenses</u>	<u>125,489</u>	<u>75,936</u>	<u>32,319</u>	<u>22,254</u>	<u>3,133</u>	<u>7,059</u>	<u>266,190</u>
Operating Income(Loss)	12,388	29,999	992	(2,518)	(285)	(7,102)	33,474

	(Millions of Yen)						
for the Half Year ended;	<b>Sep 30</b>						
	<b>2002</b>						
	<b>Imaging</b>	<b>Medical</b>	<b>Life Science</b>	<b>Industrial</b>	<b>Others</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	106,836	96,499	30,901	22,279	3,440	(82)	259,873
<u>Operating Expenses</u>	<u>99,664</u>	<u>70,144</u>	<u>30,134</u>	<u>22,468</u>	<u>4,765</u>	<u>4,217</u>	<u>231,392</u>
Operating Income(Loss)	7,172	26,355	767	(189)	(1,325)	(4,299)	28,481

	(Millions of Yen)						
<b>Variance</b>							
	<b>Imaging</b>	<b>Medical</b>	<b>Life Science</b>	<b>Industrial</b>	<b>Others</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	31,041	9,436	2,410	(2,543)	(592)	39	39,791
<u>Operating Expenses</u>	<u>25,825</u>	<u>5,792</u>	<u>2,185</u>	<u>(214)</u>	<u>(1,632)</u>	<u>2,842</u>	<u>34,798</u>
Operating Income(Loss)	5,216	3,644	225	(2,329)	1,040	(2,803)	4,993

OPERATING INCOME BY SEGMENT (Region)

**By Region** (Millions of Yen)

---

for the Half Year ended; **Sep 30 2003**

---

	<b>Japan</b>	<b>Americas</b>	<b>Europe</b>	<b>Asia</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	<b>215,160</b>	<b>88,179</b>	<b>98,908</b>	<b>66,004</b>	<b>(168,587)</b>	<b>299,664</b>
Operating Expenses	<b>189,090</b>	<b>80,657</b>	<b>93,904</b>	<b>61,397</b>	<b>(158,858)</b>	<b>266,190</b>
Operating Income(Loss)	<b>26,070</b>	<b>7,522</b>	<b>5,004</b>	<b>4,607</b>	<b>(9,729)</b>	<b>33,474</b>

(Millions of Yen)

---

for the Half Year ended; **Sep 30 2002**

---

	<b>Japan</b>	<b>Americas</b>	<b>Europe</b>	<b>Asia</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	185,449	85,636	73,969	38,833	(124,014)	259,873
Operating Expenses	<u>161,743</u>	<u>81,542</u>	<u>70,619</u>	<u>36,382</u>	<u>(118,894)</u>	<u>231,392</u>
Operating Income(Loss)	23,706	4,094	3,350	2,451	(5,120)	28,481

(Millions of Yen)

---

**Variance**

---

	<b>Japan</b>	<b>Americas</b>	<b>Europe</b>	<b>Asia</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	29,711	2,543	24,939	27,171	(44,573)	39,791
Operating Expenses	27,347	(885)	23,285	25,015	(39,964)	34,798
Operating Income(Loss)	2,364	3,428	1,654	2,156	(4,609)	4,993

# INCOME STATEMENT (FORECAST)

(Millions of Yen)					
For the Year ended:	31-Mar 2003	<b>31-Mar 2004</b>		Growth (%)	
	(Results)	(Forecast)			
Net Sales	564,343	100.0%	<b>660,000</b>	100.0%	17.0%
<u>Cost of Sales</u>	<u>293,532</u>	52.0%	<b><u>339,000</u></b>	51.4%	
Gross Profit	270,811	48.0%	<b>321,000</b>	48.6%	18.5%
<u>S.G.A. Expenses</u>	<u>208,465</u>	37.0%	<b><u>251,000</u></b>	38.0%	
Operating Income	62,346	11.0%	<b>70,000</b>	10.6%	12.3%
Other Income	4,413		<b>5,000</b>		
<u>Other Expenses</u>	<u>14,343</u>		<b>15,000</b>		
<u>Extraordinary Item</u>	<u>-9,302</u>		<b><u>4,000</u></b>		
Income Before Taxes	43,114	7.6%	<b>64,000</b>	9.7%	48.4%
<u>Provision for Taxes</u>	<u>18,766</u>		<b><u>27,000</u></b>		
Net Income	24,348	4.3%	<b>37,000</b>	5.6%	52.0%
Average Exchange Rate for Sales					
Yen / U.S.Dollar	121.95		<b>114.00</b>		-6.5%
Yen / Euro	121.04		<b>129.00</b>		6.6%
Favorable/Unfavorable Impact on Sales					
U.S.Dollar	-5,303		<b>-14,600</b>		
Euro	12,158		<b>12,000</b>		
<u>Others</u>	<u>1,442</u>		<b><u>-1,100</u></b>		
Total	8,297		<b>-3,700</b>		
R & D Expenditures	34,735	6.2%	<b>38,000</b>	5.8%	9.4%
Capital Investments	34,619		<b>33,000</b>		-4.7%
Depreciation	16,858		<b>20,000</b>		18.6%

## SALES BY PRODUCT (FORECAST)

(Millions of Yen)

For the Year ended:		31-Mar		31-Mar		Growth(%)		
		2003		2004				
		(Results)		(Forecast)				
<b>Imaging</b>	<b>Cameras</b>	Domestic	4,879		2,000		-59.0%	
		Overseas	<u>49,083</u>		<u>29,000</u>		-40.9%	
		Total	53,962	9.6%	31,000	4.7%	-42.6%	
	<b>Digital Cameras</b>	Domestic	35,056		56,300		60.6%	
		Overseas	<u>139,787</u>		<u>215,700</u>		54.3%	
		Total	174,843	31.0%	272,000	41.2%	55.6%	
	<b>Voice Recorders</b>	Domestic	1,519		1,800		18.5%	
		Overseas	<u>10,089</u>		<u>11,200</u>		11.0%	
		Total	11,608	2.1%	13,000	2.0%	12.0%	
	<b>Digital Storage</b>	Domestic	4,231		3,950		-6.6%	
		Overseas	<u>170</u>		<u>50</u>		-70.6%	
		Total	4,401	0.8%	4,000	0.6%	-9.1%	
	<b>Total</b>	Domestic	45,685		64,050		40.2%	
		Overseas	<u>199,129</u>		<u>255,950</u>		28.5%	
		Total	244,814	43.4%	320,000	48.5%	30.7%	
<b>Medical</b>	<b>Endoscopes</b>	Domestic	36,265		40,500		11.7%	
		Overseas	<u>93,742</u>		<u>95,500</u>		1.9%	
		Total	130,007	23.0%	136,000	20.6%	4.6%	
	<b>MIP (*)</b>	Domestic	21,835		23,100		5.8%	
		Overseas	<u>49,670</u>		<u>58,900</u>		18.6%	
		Total	71,505	12.7%	82,000	12.4%	14.7%	
	<b>Total</b>	Domestic	58,100		63,600		9.5%	
		Overseas	<u>143,412</u>		<u>154,400</u>		7.7%	
		Total	201,512	35.7%	218,000	33.0%	8.2%	
	<b>Life Science</b>	<b>Microscopes(Research)</b>	Domestic	11,747		13,200		12.4%
			Overseas	<u>21,404</u>		<u>23,100</u>		7.9%
			Total	33,151	5.9%	36,300	5.5%	9.5%
<b>Blood Analyzers</b>		Domestic	7,314		8,400		14.8%	
		Overseas	<u>26,477</u>		<u>30,300</u>		14.4%	
		Total	33,791	6.0%	38,700	5.9%	14.5%	
<b>Total</b>		Domestic	19,061		21,600		13.3%	
		Overseas	<u>47,881</u>		<u>53,400</u>		11.5%	
		Total	66,942	11.9%	75,000	11.4%	12.0%	
<b>Industrial</b>		<b>Microscopes(Industrial)</b>	Domestic	7,464		8,600		15.2%
			Overseas	<u>9,499</u>		<u>9,400</u>		-1.0%
			Total	16,963	3.0%	18,000	2.7%	6.1%
	<b>Endoscopes(Industrial)</b>	Domestic	1,370		1,500		9.5%	
		Overseas	<u>7,875</u>		<u>8,300</u>		5.4%	
		Total	9,245	1.6%	9,800	1.5%	6.0%	
	<b>Printers</b>	Domestic	971		2,400		147.2%	
		Overseas	<u>3,851</u>		<u>1,900</u>		-50.7%	
		Total	4,822	0.9%	4,300	0.7%	-10.8%	
	<b>Bar-Code Scanners</b>	Domestic	460		500		8.7%	
		Overseas	<u>11,043</u>		<u>8,200</u>		-25.7%	
		Total	11,503	2.0%	8,700	1.3%	-24.4%	
	<b>Others</b>	Domestic	1,403		1,050		-25.2%	
		Overseas	<u>527</u>		<u>150</u>		-71.5%	
		Total	1,930	0.3%	1,200	0.2%	-37.8%	
	<b>Total</b>	Domestic	11,668		14,050		20.4%	
		Overseas	<u>32,795</u>		<u>27,950</u>		-14.8%	
		Total	44,463	7.9%	42,000	6.4%	-5.5%	
	<b>Others</b>	Domestic	6,507		5,000		-23.2%	
		Overseas	<u>105</u>		<u>0</u>		-	
		Total	6,612	1.2%	5,000	0.8%	-24.4%	
<b>Total</b>	Domestic	141,021		168,300		19.3%		
	Overseas	<u>423,322</u>		<u>491,700</u>		16.2%		
	Total	564,343	100.00%	660,000	100.00%	17.0%		

\* MIP: Endoscopes (Surgical), Endo-Therapy Accessories, Ultrasonic Endoscopes, Bronchoscopes

## OPERATING INCOME BY SEGMENT

<b>By Product Group</b>	(Millions of Yen)						
for the Half Year ended;	<b>March 31</b>						
	<b>2004 (Forecast)</b>						
	<b>Imaging</b>	<b>Medical</b>	<b>Life Science</b>	<b>Industrial</b>	<b>Others</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	<b>320,000</b>	<b>218,000</b>	<b>75,000</b>	<b>42,000</b>	<b>5,000</b>		<b>660,000</b>
<u>Operating Expenses</u>	<u><b>292,000</b></u>	<u><b>158,000</b></u>	<u><b>71,700</b></u>	<u><b>45,000</b></u>	<u><b>7,300</b></u>	<u><b>16,000</b></u>	<u><b>590,000</b></u>
Operating Income(Loss)	<b>28,000</b>	<b>60,000</b>	<b>3,300</b>	<b>(3,000)</b>	<b>(2,300)</b>	<b>(16,000)</b>	<b>70,000</b>

	(Millions of Yen)						
for the Half Year ended;	<b>March 31</b>						
	<b>2003 (Results)</b>						
	<b>Imaging</b>	<b>Medical</b>	<b>Life Science</b>	<b>Industrial</b>	<b>Others</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	244,877	201,525	66,944	44,508	6,613	(124)	564,343
<u>Operating Expenses</u>	<u>226,675</u>	<u>146,900</u>	<u>63,651</u>	<u>45,402</u>	<u>9,282</u>	<u>10,087</u>	<u>501,997</u>
Operating Income(Loss)	18,202	54,625	3,293	(894)	(2,669)	(10,211)	62,346

	(Millions of Yen)						
<b>Variance</b>							
	<b>Imaging</b>	<b>Medical</b>	<b>Life Science</b>	<b>Industrial</b>	<b>Others</b>	<b>Elimination Unallocation</b>	<b>Consolidated Total</b>
Net Sales	75,123	16,475	8,056	(2,508)	(1,613)	124	95,657
<u>Operating Expenses</u>	<u>65,325</u>	<u>11,100</u>	<u>8,049</u>	<u>(402)</u>	<u>(1,982)</u>	<u>5,913</u>	<u>88,003</u>
Operating Income(Loss)	9,798	5,375	7	(2,106)	369	(5,789)	7,654

## BALANCE SHEET

	(Millions of Yen)		
	31-Mar 2003	<b>30-Sep 2003</b>	Variance
Cash and time deposits	102,216	<b>132,678</b>	30,462
Marketable securities	34,997	<b>34,997</b>	0
Notes and accounts receivable	104,190	<b>102,129</b>	-2,061
Allowance for doubtful accounts	-3,647	<b>-3,399</b>	248
Inventories	77,166	<b>82,419</b>	5,253
Deferred income taxes	21,887	<b>24,381</b>	2,494
Others	20,740	<b>28,969</b>	8,229
<b>Current Assets</b>	<b>357,549</b>	<b>402,174</b>	<b>44,625</b>
Land	15,230	<b>15,217</b>	-13
Buildings and structures	87,446	<b>87,473</b>	27
Machinery and equipment	143,332	<b>148,068</b>	4,736
Construction in progress	878	<b>2,033</b>	1,155
	246,886	<b>252,791</b>	5,905
Less-Accumulated depreciation	-155,591	<b>-158,097</b>	-2,506
<b>Net property, plant and equipment</b>	<b>91,295</b>	<b>94,694</b>	<b>3,399</b>
Investment securities	107,895	<b>115,205</b>	7,310
Deferred income taxes	17,408	<b>16,267</b>	-1,141
Lease deposits and others	31,621	<b>34,859</b>	3,238
<b>Total investments and other assets</b>	<b>156,924</b>	<b>166,331</b>	<b>9,407</b>
<b>Total Assets</b>	<b>605,768</b>	<b>663,199</b>	<b>57,431</b>

	(Millions of Yen)		
	31-Mar 2003	<b>30-Sep 2003</b>	Variance
Short-term borrowings	76,249	<b>93,752</b>	17,503
Current maturities of long-term debt	35,000	<b>20,000</b>	-15,000
Notes and accounts payable	60,860	<b>66,884</b>	6,024
Accrued expenses	59,439	<b>61,247</b>	1,808
Income tax payable	12,304	<b>11,529</b>	-775
Other current liabilities	33,963	<b>36,314</b>	2,351
<b>Current Liabilities</b>	<b>277,815</b>	<b>289,726</b>	<b>11,911</b>
Long-term debt, less current maturities	84,778	<b>115,425</b>	30,647
Severance and retirement allowance	14,043	<b>16,510</b>	2,467
Other non-current liabilities	5,820	<b>3,944</b>	-1,876
Minority interest	880	<b>1,097</b>	217
Common stock	40,833	<b>40,833</b>	0
Additional paid-in capital	65,528	<b>65,528</b>	0
Retained earnings	119,867	<b>133,298</b>	13,431
Net unrealized holding losses on securities	555	<b>4,445</b>	3,890
Foreign currency translation adjustments	-3,324	<b>-6,328</b>	-3,004
Treasury stock, at cost	-1,027	<b>-1,279</b>	-252
<b>Shareholders' Equity</b>	<b>222,432</b>	<b>236,497</b>	<b>14,065</b>
<b>Liabilities and Shareholder's Equity</b>	<b>605,768</b>	<b>663,199</b>	<b>57,431</b>